转人IL-2基因对原代肾细胞癌致瘤性的影响

Loss of Tumorigenicity of the Primary Renal Cell Carcinoma by Transduced with Human IL-2 Gene

目的 研究转人IL 2基因对原代肾细胞癌 (RCC )细胞致瘤性的影响 ,为RCC的基因治疗打下基础。方法 将人IL 2基因与逆转录病毒载体 pLNCX连接 ,转染包装细胞 ,经鉴定后 ,感染原代RCC细胞 ,采用MTT法检测转人IL 2基因的原代RCC的IL 2的活性。然后 ,将转人IL 2基因的原代RCC和未转基因原代RCC分别接种裸鼠 ,观测转IL 2前后RCC细胞致瘤性的变化。结果 转人IL 2的RCC细胞IL 2的生物学活性平均为 (2 44± 5 2 )U /ml ,接种裸鼠后无肿瘤长出。结论 转人IL 2基因使原代RCC失去了致瘤性 ,转人IL 2基因的RCC细胞可作为瘤苗用于肾细胞癌的治疗。

Objective To study the tumorigenicity of the human renal cell carcinoma(RCC)cells transduced with human IL-2 gene.Methods Recombinant retroviral vector pLNC(IL-2) was constructed and transfected into the packaged cell.The primary RCC cells were infected with confirmed retrovirus and the biological activity of rhIL-2 was tested by MTT method.Then,primary RCC cell,infected with the hIL-2 gene or not,was injected into nude mice and the tumorigenecity of RCC was observed.Results The biological activity of rhIL-2 in the recominbinant retrovirus supernants was meanly(244±52) U/ml.The nude mice injected with IL-2 gene engineered RCC cells had no tumor growth.Conclusion The IL-2 gene engineered human RCC cells lost tumorigenicity.The primary RCC cells transduced with human IL-2 gene might be as tumor vaccine for the treatment of RCC.